Sight Sciences (NASDAQ:SGHT) Stock Keeps “Overweight” Rating at Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Sight Sciences (NASDAQ:SGHT) in a research report report published on Thursday,Benzinga reports. The firm currently has a $12.00 target price on the stock, up from their previous target price of $9.00.

Several other equities research analysts have also recently issued reports on the stock. UBS Group raised their price target on shares of Sight Sciences from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen upgraded shares of Sight Sciences from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sight Sciences in a research report on Friday, August 7th. HC Wainwright started coverage on shares of Sight Sciences in a research note on Thursday, October 15th. They set a “buy” rating and a $14.00 price objective on the stock. Finally, Citigroup upped their price objective on shares of Sight Sciences from $8.00 to $10.00 and gave the company a “neutral” rating in a research note on Monday, October 5th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.62.

Sight Sciences Stock Performance

Sight Sciences stock opened at $9.76 on Thursday. Sight Sciences has a fifty-two week low of $3.38 and a fifty-two week high of $10.31. The company has a market capitalization of $537.68 million, a price-to-earnings ratio of -18.77 and a beta of 2.44. The stock has a fifty day moving average of $8.68 and a two-hundred day moving average of $6.07. The company has a debt-to-equity ratio of 0.58, a quick ratio of 4.67 and a current ratio of 4.95.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The business had revenue of $24.92 million for the quarter, compared to the consensus estimate of $23.55 million. Sight Sciences had a negative return on equity of 42.41% and a negative net margin of 32.13%. On average, analysts anticipate that Sight Sciences will post -0.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other Sight Sciences news, CTO David Badawi sold 7,797 shares of Sight Sciences stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $9.05, for a total value of $70,562.85. Following the completion of the sale, the chief technology officer owned 1,975,075 shares in the company, valued at $17,874,428.75. The trade was a 0.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Paul Badawi sold 29,653 shares of Sight Sciences stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.05, for a total value of $268,359.65. Following the completion of the sale, the chief executive officer owned 6,092,819 shares of the company’s stock, valued at $55,140,011.95. This trade represents a 0.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 47,646 shares of company stock valued at $429,157 in the last quarter. Corporate insiders own 30.40% of the company’s stock.

Hedge Funds Weigh In On Sight Sciences

Several institutional investors and hedge funds have recently bought and sold shares of SGHT. Hsbc Holdings PLC boosted its holdings in shares of Sight Sciences by 21.6% in the 2nd quarter. Hsbc Holdings PLC now owns 46,707 shares of the company’s stock valued at $255,000 after purchasing an additional 8,297 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Sight Sciences during the 2nd quarter worth $520,000. Canada Pension Plan Investment Board acquired a new stake in shares of Sight Sciences during the 2nd quarter worth $299,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Sight Sciences during the 2nd quarter worth $60,000. Finally, Algert Global LLC raised its position in shares of Sight Sciences by 25.3% in the 2nd quarter. Algert Global LLC now owns 28,266 shares of the company’s stock worth $153,000 after buying an additional 5,706 shares during the period. Institutional investors and hedge funds own 55.51% of the company’s stock.

Key Stories Impacting Sight Sciences

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Higher 2026 outlook: Sight Sciences raised its full-year revenue guidance to $92–$93 million and indicated a higher 2026 revenue target for its iDose product. The improved outlook may support expectations for continued growth. Article: Sight Sciences signals 2026 revenue outlook
• Positive Sentiment: CMS reimbursement development: CMS established a direct practice-expense supply code for TearCare SmartLids, a single-use component of the TearCare system. This could help clarify reimbursement and support adoption. Article: CMS establishes a TearCare SmartLids supply code
• Positive Sentiment: Revenue beat and analyst support: Third-quarter revenue was $24.92 million, above analysts’ $23.55 million estimate. Piper Sandler reaffirmed its Overweight rating and raised its price target to $12 from $9, signaling confidence in further upside. Analyst rating information
• Neutral Sentiment: Losses persist, but met expectations: SGHT reported a third-quarter loss of $0.12 per share, in line with consensus and narrower than the $0.16 loss a year earlier. The company remains unprofitable, which may temper the positive growth news. Article: Sight Sciences reports Q3 loss and revenue beat

Sight Sciences Company Profile

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.